Therefore, an increasing number of studies have focused on targeting A2AR. In the mouse model of chronic lymphoblastic leukemia, targeting A2AR had no effect on the size and weight of the tumor but saved the dysfunction of immune cells by reducing the accumulation of Tregs, restoring the expression of CD107a on T cells, and increasing the secretion of IL-2 and IFN-γ, indicating that anti-A2AR affects the function of immune cells rather than tumor cells [130,131,132]. This evidence concerns the gene IFNG and neoplasm.